Jeanette presents E-poster at IPVC 2021
The virtual 34th International Papillomavirus Conference took place last week, from November 15-19. The conference’s theme this year was: ‘Research and education for HPV elimination’.
Jeanettes E-Poster ‘A Candidate Broadly Protective HPV-Vaccine Targeting the L2 Minor Protein Demonstrates Promising Results in a Clinical Phase I Trial’ was selected for the ‘Featured E-posters’ section (no. 97), as part of the conference.
HPV research
Current HPV vaccines are based on L1 proteins and protects against nine HPV types, this still leaves out a panel of other relevant HPV types unaddressed, in particular beta-HPV types involved in the development of non-melanoma skin cancer (NMSC). In seeking broader protection, 2A Pharma has recently completed a first-in-human study using the AAVLP vaccine carrier to target the more conserved HPV-L2 proteins.
The E-poster includes preliminary results of our first-in-human study using the AAVLP vaccine carrier to target the conserved HPV-L2 proteins.
About IPVC
The aim of the conference is to present the latest research results and share knowledge through workshops, lectures, and (poster) presentations on papillomavirus-related topics, with a particular emphasis on HPV elimination.
